IMPORTANCE Epidermal growth factor receptor (EGFR) (HER1) signaling depends on ligand binding and dimerization with itself or other HER receptors. We previously showed in a randomized trial that high EGFR ligand expression is predictive of panitumumab benefit in advanced colorectal cancer. Tumor expression of HER3 may further refine the RAS wild-type (wt) population benefitting from anti-EGFR agents.
W
hile RAS mutations identify patients with advanced colorectal cancer (aCRC) who will not benefit from anti-epidermal growth factor receptor (anti-EGFR) agents, 1 RAS wild type (wt) status does not reliably predict who will. 2 We recently published clinical validation of combined tumor messenger RNA (mRNA) overexpression of the EGFR ligands amphiregulin (AREG) and epiregulin (EREG) as a predictive biomarker for panitumumab in RAS-wt aCRC 3 in a large randomized clinical trial (PICCOLO [Panitumumab, Irinotecan, and Ciclosporin in COLOrectal cancer], a study of irinotecan-panitumumab [IrPan] vs irinotecan alone for second-line treatment of KRAS-wt aCRC).
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The activity of agents targeting EGFR (HER1) may also depend on interactions with other HER receptors. HER family interdependence is well documented 4 ; HER3, unlike other HER receptors, cannot generate signaling through homodimerization but is an obligate heterodimer, predominantly with EGFR or HER2. 5 The equilibrium between HER3 heterodimers may be a key factor in downstream EGFR family signaling. [6] [7] [8] We investigate the role of HER3 tumor mRNA expression in aCRC in pretreatment samples from the PICCOLO trial, first as a prognostic biomarker, then as a predictive biomarker for panitumumab efficacy. We further investigate its relationship with AREG and EREG, with a view to future development as a clinically applicable selection tool.
Methods
Following United Kingdom national ethics committee approval, written consent was obtained for the retrieval of stored tumor blocks.
The results of the PICCOLO trial 2 have been reported
previously. This study includes all patients with adequate stored tumor material. Ribonucleic acid was extracted from formalin-fixed, paraffin-embedded tissue sections and HER3 expression measured by reverse transcription polymerase chain reaction (primer sequences are shown in eTable 1 in the Supplement). The primary end point was progression-free survival (PFS); secondary end points were overall survival (OS) and 12-week response rate. The primary analysis assessed HER3 expression as a continuous variable (log-transformed to base 2). In a planned exploratory analysis, HER3 expression was assessed as a dichotomous variable, using a range of cut points to achieve optimum discrimination for interaction between biomarker and treatment. Further details are provided in the Supplement. 
Key Points
Question Can tumor messenger RNA (mRNA) expression of HER3 predict response to anti-epidermal growth factor receptor (anti-EGFR) agents in RAS wild type advanced colorectal cancer?
Findings In this analysis of patients in a large phase 3 trial of irinotecan with and without panitumumab, patients with RAS wild type whose tumors had high HER3 mRNA expression benefitted markedly from panitumumab, but patients with RAS wild type whose tumors had low HER3 expression gained no benefit. Interaction between the biomarker and the treatment was significant.
Meaning Tumor HER3 mRNA expression may be a useful predictive biomarker for anti-EGFR therapy in RAS wild-type colorectal cancer; further study is warranted.
Results
Three hundred and thirty-one patients had adequate tumor material for RNA extraction; HER3 expression measurement was successful in 308. Baseline characteristics by treatment arm were well balanced (eTable 2 in the Supplement), with no significant differences from the overall trial population. RAS/RAF genotype data 61, 146; 61; and BRAF V600E) were available for all cases. Of 308 patients, 209 (67.8%) were wt for all KRAS/NRAS codons and form the primary analysis population for this study (eFigure 1 in the Supplement). HER2 expression data were available for 210 of 308 (68%) patients 9 ; however, overexpression was found in only 3 of 210 (1.4%), precluding meaningful analysis. HER3 was not significantly associated with RAS mutation status, but was lower in BRAF-mutant and PIK3CA-mutated groups compared with wt. HER3 levels were weakly positively correlated with both AREG and EREG levels (Spearman ρ correlation, 0.26 for each; P < .001). In patients with RAS wt, HER3 levels were lower in right-sided compared with left-sided tumors, but there was no association in the whole population.
Higher log2 HER3 was prognostic for improved OS (hazard ratio [HR] per 2-fold change, 0.91; 95% CI, 0.83-0.99; P = .04) but not for PFS (HR, 0.93; 95% CI, 0.83-1.05; P = .25) in the whole population (eTable 3 in the Supplement).
In patients with RAS wt, increasing HER3 expression was significantly predictive for panitumumab benefit to PFS (IrPan: HR, 0.71; 95% CI, 0.61-0.82 per 2-fold increase; P < .001 vs irinotecan: HR, 0.96; 95% CI, 0.82-1.13; P = .65). Interactions were significant (unadjusted P = .001) ( Table 1 ). Estimates were similar after adjusting for performance status and previous response, with significant interaction (P = .003). HER3 was also significantly predictive for panitumumab benefit on OS in patients with RAS wt (IrPan: HR, 0.73; 95% CI, 0.64-0.83; P < .001 vs irinotecan: HR, 0.93; 95% CI, 0.83-1.05; P = .25). Interactions were significant (unadjusted P = .004; adjusted P = .01) ( Table 1 ). This effect was independent of BRAF mutation status and primary tumor location (eTable 4 in the Supplement).
Preplanned predictive analyses of HER3 expression dichotomized at the 50th, 66th, 80th, and 90th percentiles in patients with RAS wt (eTable 5 in the Supplement) showed that at the 66th percentile, there was no PFS benefit from panitumumab in low expressers (median PFS, 3.3 months [IrPan] vs 4.3 months [irinotecan]; HR, 0.96; 95% CI, 0.67-1.38; P = .84), clear benefit in high expressers (HR, 0.33; 95% CI, 0.19-0.58; P < .001) ( Figure) , and strong evidence for interaction. Secondary analyses adjusting for performance status and previous response showed similar estimates. This cut point was therefore selected for all subsequent analyses to define "HER3-high" and "HER3-low" populations. Dichotomized HER3 was also predictive for OS in patients with RAS wt, though here the interaction was driven in part by a negative impact of panitumumab in patients with low HER3 expression. In patients with RAS wt and high HER3 expression, median OS was 14.6 months (IrPan) vs 13.2 months (irinotecan) (HR, 0.66; 95% CI, 0.40-1.10; P = .11), while in patients with RAS wt and low HER3 expression, median OS was 8.3 months (IrPan) vs 10.3 months (irinotecan) (HR, 1.56; 95% CI, 1.09-2.23; P = .02), with significant interaction (P = .01) (Table 2 and Figure) . Secondary analyses adjusting for performance status and previous response showed similar estimates for interaction (P = .02). The dichotomized HER3 model was also independent of BRAF mutation status and primary tumor location (eTable 4 in the Supplement).
Dichotomized HER3 was not significantly prognostic for OS (HR, 0.85; 95% CI, 0.60-1.20; P = .35) or PFS (HR, 1.03; 95% CI, 0.73-1.45; P = .86) (eTable 3 and eFigure 2 in the Supplement).
In patients with RAS wt and high HER3 expression, 12-week response rate was 48.6% (IrPan) vs 12.1% (irinotecan) (relative risk, 4.01; 95% CI, 1.50-10.68), while in patients with RAS wt and low HER3 expression response rate was 24.6% (IrPan) vs 11.1% (irinotecan) (relative risk, 2.21; 95% CI, 1.03-4.75; interaction P = .34) (eTable 6 in the Supplement). We previously reported 3 that in a dichotomous ligand mRNA expression model, "EREG-high and/or AREG-high" was strongly predictive of panitumumab PFS benefit in patients with RAS wt, and that as a continuous variable AREG was the more predictive of the 2 ligands.
As continuous variables in a joint model, HER3 and AREG were independent predictors of IrPan PFS benefit, while for OS the evidence was equivocal (eTable 7 in the Supplement).
In an exploratory dichotomous model, the RAS wt population was divided into 4 groups: high HER3, high AREG/ EREG (n = 42); high HER3, low AREG/EREG (n = 27); low HER3/high AREG/EREG (n = 53); and low HER3, low AREG/ EREG (n = 87). Marked panitumumab benefit was observed in the high-HER3, high-AREG/EREG group (PFS HR, 0.24; 95% CI, 0.11-0.51; P < .001 and OS HR, 0.36; 95% CI, 0.18-0.73; P = .004). Conversely, the low-HER3, low-AREG/EREG group showed no evidence of benefit (PFS HR, 1.14; 95% CI, 0.73-1.79; P = .57 and OS HR, 1.44; 95% CI, 0.92-2.26; P = .11).
Patients in the 2 intermediate groups had intermediate effects for PFS (eTable 8 in the Supplement).

Discussion
To our knowledge, the work described herein represents the largest dedicated analysis of HER3 expression in aCRC to date. We found no evidence for HER3 as a prognostic marker but found HER3 overexpression to be significantly associated with benefit from panitumumab.
Overall in PICCOLO 2 panitumumab produced a significant improvement in PFS but not OS. It is therefore encouraging that HER3 was significantly predictive for OS as well as PFS. Furthermore, in our combined HER3-and-ligands model, patients with high-HER3, high-AREG/EREG tumors achieved marked and significant OS benefit with panitumumab (HR, 0.36; 95% CI, 0.18-0.73; P = .004). These findings are interesting but must be treated with caution, especially given that the HER3 cut point for dichotomization was derived internally from this data set. The interaction between HER3 expression and anti-EGFR agent efficacy in aCRC has been studied previously in 2 smaller series. 9, 10 In these studies HER3 overexpression was associated with inferior clinical outcomes with anti-EGFR agents. The present study is a dedicated comprehensive analysis in a mature, large, randomized trial, allowing for adjustments for likely confounders. Preclinical work supports both hypotheses: heregulin activation of HER3 might trigger an alternate signaling pathway circumventing EGFR blockade, 8, 11 supporting HER3 overexpression as a negative predictive marker. Alternatively, given its role as an obligate heterodimer, HER3 expression could identify those tumors most reliant on EGFR signaling through autocrine feedback loops, and more likely to respond to EGFR-targeted agents.
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Limitations
These findings are interesting, but results should be treated with caution, especially given that the HER3 cut point for dichotomization was derived internally from this dataset. Additionally, tissue was available for only 331 (47.6%) of the 696 patients in the IrPan vs irinotecan randomization in PICCOLO.
Conclusions
This study suggests that high HER3 expression is related to anti-EGFR agent activity in aCRC and may offer a clinically useful selection biomarker. Prior to clinical application, revalidation of the findings and refining of the cut point is required, in well-designed hypothesis-based studies using other randomized data sets. 
Laboratory methods:
Formalin-fixed, paraffin-embedded tumor tissue was retrieved, anonymized and encoded with the patient's trial number at the treating hospital, then sent to the research laboratory. Here, all staff were blind to the patients' treatment allocation and clinical outcomes. The laboratory processing and storage of samples was under Ethical approval, and the laboratory adheres where possible to GCLP guidelines and participates annually in the UK National External Quality Assessment Service (NEQAS) scheme.
Areas containing the highest density of tumour cells were identified on a hematoxylin and eosin stained section. Six to nine 5 µm sections were used per extraction, depending upon the tumour area per slide. RNA was extracted using the RNeasy FFPE kit (Qiagen, Venlo, Netherlands), according to the manufacturers instructions.
Quantitative RT-PCR analysis
Following RNA extraction, HER3 mRNA expression was assessed by reverse transcriptase polymerase chain reaction (RT-PCR). Firstly DNA digestion with DNase I was added to the manufacturer's protocol then reverse transcription performed with 220 units of Superscript II Reverse Transcriptase (Life Technologies, Carlsbad, CA) per reaction and was followed by quantitative RT-PCR using a 7500 Real Time PCR System (applied Biosystems, Foster City, CA). HER3 expression was measured in duplicate and normalized against a set of three reference genes (GAPDH, UBC, and RPL13A; primer sequences in Supplementary Table 1 ). Reference gene stability was assessed with the geNorm algorithm implemented in qBasePlus software (Biogazelle). Inter-run variability was corrected using five inter-run calibrators constituting a ten-fold dilution series derived from an equimolar mixture of synthetic nucleic acid standards consisting of the gene-specific PCR target regions. Standard sequences are shown in web-appendix Table 1 .
Calibrated normalized relative quantities (CNRQ) were calculated relative to the synthetic standards with qBasePlus 1.1 software using target-specific PCR efficiencies calculated from the inter-run calibration standard curves (Biogazelle, Ghent, Belgium; http://www.qbaseplus.com). 
Supplementary
Statistical Methods
STATA was used for all statistical analyses (Stata Statistical Software: Release 12 (2011) , StataCorp). Baseline patient characteristics were compared between treatment arms using two-tailed T-tests, Wilcoxon rank sum tests (for non-normally distributed variables) and Pearson Chi-squared tests (for categorical variables). Patient characteristics were compared to the whole trial population using the same tests. Boxplots were produced of raw HER3 expression.
Three clinical endpoints were used: primary endpoint was PFS; secondary endpoints were OS and 12-week response rate (RR). PFS and RR data were unchanged from data presented in the primary clinical paper,[3] but updated OS data was used in this analysis (additional 2 year follow up).
HER3 expression was first assessed as a prognostic marker in patients treated with irinotecan alone, using unadjusted Cox proportional hazards models. HER3 expression was then assessed as a predictive marker for panitumumab benefit upon PFS and OS by testing for interaction using a likelihood ratio test to compare a model including the main effects for log 2 HER3 and treatment (IrPan versus Ir) plus the log 2 HER3*treatment interaction term with a model including only the main effects.. Adjustment was then performed for significant prognostic factors in the trial population (performance status [PS] ; previous response to first line treatment). Secondary analysis of predictive effects was performed in patients with RAS, BRAF and PIK3CA mutations, and primary tumour location (PTL).
The primary analyses were conducted on the basis of HER3 expression (log-transformed to base 2) as a continuous variable. In a planned exploratory analysis, in order to visualize the future potential for the use of HER3 as a clinical decision-making tool, we then examined the impact of panitumumab treatment in patient groups dichotomized by HER3 expression, using a range of cut-points (50 th , 66 th , 80 th and 90 th centiles, Supplementary Table 5 ). The aim was to achieve optimum discrimination for biomarker/treatment interaction, i.e., to identify two groups with estimated hazard ratios for panitumumab effect close to 1 versus clear benefit, with strong statistical evidence for interaction. The 66 th centile cut-point was used in the secondary analyses to classify high versus low HER3 expression as it demonstrated the strongest biomarker/treatment interaction; this showed a protective effect for Irpan versus Ir on PFS in the high HER3 expressors ) but no effect in the low HER3 expressors ) with a highly significant interaction (p=0.002). At the 80 th centile there was some suggestion of benefit in the low HER3 group (unadjusted HR=0.84 (0.61-1.17)) (Supplementary Table 5 ). Next, to explore the relationship between HER3 expression and EGFR ligand expression, survival models were used to estimate the joint effects of EREG/AREG and HER3, primarily as continuous but also as dichotomous variables.
Relative risks were estimated from generalized linear models (with a log link) for the 12-week RR outcome, with 12 weeks response rate in Ir treated patients used as the referenc . 
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